Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Connective Tissue Diseases: early-phase trial registry

2 of 6 indexed Connective Tissue Diseases trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Connective Tissue Diseases: 6 US clinical trials tracked, 2 recruiting.

Connective Tissue Diseases is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Cumberland Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition connective-tissue-diseases

OPEN 2 | RECR 33% | LATE 1 | EARLY 3 | RANK #2866 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Connective Tissue Diseas (th…33%
Open-enrollment share among volume-matched conditions near Connective Tissue Diseases

Connective Tissue Diseases lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Connective Tissue Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Connective Tissue Diseases is recruiting below its size-band peers.

    2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Connective Tissue Diseases research.

    Cumberland Pharmaceuticals accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Connective Tissue Diseases trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.

  4. Connective Tissue Diseases splits between interventional and observational designs.

    4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22Phase 31

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 1

Named interventions

Most-linked intervention names on Connective Tissue Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) Biological
1 trials
Oral Ifetroban Drug
1 trials
129Xe Hyperpolarized Drug
1 trials
Belimumab Drug
1 trials
Oral Placebo Drug
1 trials

US sites by state

Facility locations filed on Connective Tissue Diseases trials. A trial with sites in several states counts in each.

Pennsylvania 2 trials
Maryland 2 trials
Florida 2 trials
Texas 1 trials
South Carolina 1 trials
New York 1 trials
Nebraska 1 trials
North Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Connective Tissue Diseases page

6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Connective Tissue Diseases condition card totals 6 registered trials; most-linked intervention Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs); top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.